奈达铂联合5-氟脲嘧啶治疗顺铂耐药的晚期食管癌临床疗效观察

Clinical observation of nedaplatin plus 5-fluorouracil in treatment of cisplatin-resistant advanced esophageal cancer

目的考察奈达铂联合5-氟脲嘧啶（5-Fu）对顺铂耐药的晚期食管癌的临床疗效及毒副反应。方法奈达铂80 mg.m-2静滴2 h,d1;亚叶酸钙（CF）75 mg·m-2静滴2 h后,5-FU 500 mg·m-2持续静滴6 h以上,d1～5,28 d为一周期。完成2～3个周期后,根据WHO标准评价疗效和毒副反应。结果总有效率（CR＋PR）42.4%,1年生存率29.1%;主要毒副作用为骨髓抑制。结论对顺铂耐药的晚期食管癌患者,奈达铂联合5-Fu治疗是安全有效的方案,值得临床推广。

Aim To evaluate efficacy and toxic reactions of nedaplatin plus 5-fluorouracil（5-Fu） in treatment of cisplatin-resistant advanced esophageal cancer.Methods Nedaplatin was administered at a dose of 80 mg·m-2 by drip infusion in 2 hours on day 1.Calcium folinate（CF） with a dose of 75 mg·m-2 was intravenous infused in 2 hours,followed by more than 6h continual intravenous infusion of 5-Fu with a dose of 500 mg·m-2 on d1to d5.Chemotherapy was repeatedly given every 28 days and the efficacy was evaluated by the standard of WHO after 2 to 3 cycles of administration. Results The overall response rate（ CR ＋ PR） was 42.4%. One-year survival rate was 29.1%. The major toxicity was myelosuppression. Conclusion Nedaplatin plus 5-Fu is rather active in treating cisplatin-resistant advanced esophageal cancer with acceptable tolerance, and it deserves further popularization.